{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:55Z","timestamp":1790913715840,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12288-024-01930-8","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:04:19Z","timestamp":1732032259000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of CML and Pregnancy in Low-and Middle-income Countries"],"prefix":"10.1007","volume":"41","author":[{"given":"Nitya","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimpy","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-8491","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"1930_CR1","doi-asserted-by":"publisher","unstructured":"Malhotra P, Varma S (2007) Chronic myeloid leukaemia in India. Lancet.;370(9593):1127. https:\/\/doi.org\/10.1016\/S0140-6736(07)61510-4. PMID: 17905161","DOI":"10.1016\/S0140-6736(07)61510-4"},{"issue":"2Supplementary","key":"1930_CR2","first-page":"861","volume":"33","author":"M Absar","year":"2020","unstructured":"Absar M, Akhtar T, Jameel A, Mahmood A, Ullah A, Aleem A, Qureshi K, Rehman N, Iqbal Z (2020) Long term outcome of chronic myeloid leukemia patients treated with imatinib: report from a developing country. Pak J Pharm Sci 33(2Supplementary):861\u2013870. PMID: 32863263","journal-title":"Pak J Pharm Sci"},{"key":"1930_CR3","unstructured":"https:\/\/www.worldbank.org\/en\/country\/mic accessed 16th June 2024"},{"issue":"1","key":"1930_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/jayao.2018.0007","volume":"8","author":"U Yanamandra","year":"2019","unstructured":"Yanamandra U, Sahu KK, Karunakaran P, Katoch D, Jain N, Khadwal A, Prakash G, Lad D, Naseem S, Varma N, Varma S, Malhotra P (2019) Adolescent and young adult chronic myeloid leukemia in real-world settings: experience from a Tertiary Care Institute in Northern India. J Adolesc Young Adult Oncol 8(1):94\u201397. https:\/\/doi.org\/10.1089\/jayao.2018.0007. Epub 2018 Nov 1. PMID: 30383979","journal-title":"J Adolesc Young Adult Oncol"},{"key":"1930_CR5","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186\u2013193","journal-title":"Lancet Haematol"},{"issue":"1","key":"1930_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/ijmr.ijmr_1090_21","volume":"157","author":"D Goni","year":"2023","unstructured":"Goni D, Jain A, Singh C, Jindal N, Nampoothiri R, Jandial A, Lad D, Khadwal A, Prakash G, Naseem S, Varma N, Malhotra P (2023) Feasibility of treatment-free remission with generic imatinib: results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study. Indian J Med Res 157(1):87\u201391. https:\/\/doi.org\/10.4103\/ijmr.ijmr_1090_21. PMID: 37040232; PMCID: PMC10284370","journal-title":"Indian J Med Res"},{"issue":"1","key":"1930_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/hematology.2019000050","volume":"2019","author":"H Malhotra","year":"2019","unstructured":"Malhotra H, Radich J, Garcia-Gonzalez P (2019) Meeting the needs of CML patients in resource-poor countries. Hematol Am Soc Hematol Educ Program 2019(1):433\u2013442. https:\/\/doi.org\/10.1182\/hematology.2019000050. PMID: 31808889; PMCID: PMC6913442","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1930_CR8","doi-asserted-by":"publisher","unstructured":"Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res.;34(11):1459-71. https:\/\/doi.org\/10.1016\/j.leukres.2010.03.033. PMID: 20430443","DOI":"10.1016\/j.leukres.2010.03.033"},{"key":"1930_CR9","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.eclinm.2020.100257","volume":"19","author":"CA Umeh","year":"2020","unstructured":"Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R (2020) The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine 19:100257. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100257. PMID: 32140674; PMCID: PMC7046500","journal-title":"EClinicalMedicine"},{"issue":"4","key":"1930_CR10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2. Epub 2020 Mar 3. PMID: 32127639; PMCID: PMC7214240","journal-title":"Leukemia"},{"issue":"5","key":"1930_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/bloodadvances.2020002973","volume":"5","author":"A Nasser","year":"2021","unstructured":"Nasser A, Hussein A, Chamba C, Yonazi M, Mushi R, Schuh A, Luzzatto L (2021) Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv 5(5):1403\u20131411. https:\/\/doi.org\/10.1182\/bloodadvances.2020002973. PMID: 33666650; PMCID: PMC7948290","journal-title":"Blood Adv"},{"key":"1930_CR12","doi-asserted-by":"publisher","unstructured":"Chikkodi SV, Malhotra P, Naseem S, Khadwal A, Prakash G, Sahu KK, Kumari S, Suri V, Varma N, Varma S (2015) Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk.;15 Suppl:S114-9. https:\/\/doi.org\/10.1016\/j.clml.2015.03.014. PMID: 26297263","DOI":"10.1016\/j.clml.2015.03.014"},{"issue":"9","key":"1930_CR13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/bloodadvances.2020001944","volume":"4","author":"C Singh","year":"2020","unstructured":"Singh C, Jain A, Lad D, Prakash G, Khadwal A, Bhurani D, Ahmed R, Agrawal N, Easow J, Varma N, Malhotra P (2020) Poor tolerability to ponatinib in Indian CML patients. Blood Adv 4(9):1927\u20131929. https:\/\/doi.org\/10.1182\/bloodadvances.2020001944. PMID: 32380534; PMCID: PMC7218412","journal-title":"Blood Adv"},{"key":"1930_CR14","first-page":"1","volume":"4","author":"U Yanamandra","year":"2018","unstructured":"Yanamandra U, Malhotra P, Sahu KK, Sushma Y, Saini N, Chauhan P, Gill J, Rikhi D, Khadwal A, Prakash G, Lad D, Suri V, Kumari S, Varma N, Varma S (2018) Variation in adherence measures to Imatinib Therapy. J Glob Oncol 4:1\u201310 Epub 2017 Mar 24. PMID: 30241224; PMCID: PMC6223484","journal-title":"J Glob Oncol"},{"issue":"3","key":"1930_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/ijd.13852","volume":"57","author":"K Vinay","year":"2018","unstructured":"Vinay K, Yanamandra U, Dogra S, Handa S, Suri V, Kumari S, Khadwal A, Prakash G, Lad D, Varma S, Malhotra P (2018) Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. Int J Dermatol 57(3):332\u2013338. https:\/\/doi.org\/10.1111\/ijd.13852. Epub 2017 Dec 20. PMID: 29266186","journal-title":"Int J Dermatol"},{"issue":"Suppl 1","key":"1930_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12288-014-0471-4","volume":"32","author":"KK Sahu","year":"2016","unstructured":"Sahu KK, Malhotra P, Uthamalingam P, Prakash G, Bal A, Varma N, Varma SC (2016) Chronic myeloid leukemia with Extramedullary Blast Crisis: two unusual sites with Review of Literature. Indian J Hematol Blood Transfus 32(Suppl 1):89\u201395. https:\/\/doi.org\/10.1007\/s12288-014-0471-4. Epub 2014 Oct 29. PMID: 27408365; PMCID: PMC4925471","journal-title":"Indian J Hematol Blood Transfus"},{"key":"1930_CR17","doi-asserted-by":"publisher","first-page":"107367","DOI":"10.1016\/j.leukres.2023.107367","volume":"133","author":"U Bhattacharjee","year":"2023","unstructured":"Bhattacharjee U, Jandial A, Singh C, Lekshmon KS, Mishra K, Sandal R, Nampoothiri R, Naseem S, Suri V, Jain A, Lad DP, Prakash G, Khadwal A, Malhotra P (2023) Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies. Leuk Res 133:107367. https:\/\/doi.org\/10.1016\/j.leukres.2023.107367. Epub 2023 Aug 2. PMID: 37566974","journal-title":"Leuk Res"},{"issue":"6","key":"1930_CR18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/10428194.2016.1254779","volume":"58","author":"KK Sahu","year":"2017","unstructured":"Sahu KK, Dhibar DP, Varma S, Malhotra P (2017) CML with pregnancy: real challenges in developing nations. Leuk Lymphoma 58(6):1518\u20131519. https:\/\/doi.org\/10.1080\/10428194.2016.1254779. Epub 2016 Nov 16. PMID: 27852145","journal-title":"Leuk Lymphoma"},{"key":"1930_CR19","doi-asserted-by":"publisher","unstructured":"Chang X, Zhou L, Chen X, Xu B, Cheng Y, Sun S, Fang M, Xiang Y (2017) Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase. Target Oncol.;12(6):827\u2013832. https:\/\/doi.org\/10.1007\/s11523-017-0521-6. PMID: 28791527","DOI":"10.1007\/s11523-017-0521-6"},{"issue":"1","key":"1930_CR20","doi-asserted-by":"publisher","first-page":"e33407","DOI":"10.7759\/cureus.33407","volume":"15","author":"M Abu-Tineh","year":"2023","unstructured":"Abu-Tineh M, Ali EA, Alshurafa A, Nashwan AJ, Albsheer K, Ahmed A, Hailan Y, Rozi W, Aljaloudi E, Yassin MA (2023) The impact of tyrosine kinase inhibitors on Fatherhood in patients with chronic myeloid leukemia: a mixed-method study. Cureus 15(1):e33407. https:\/\/doi.org\/10.7759\/cureus.33407. PMID: 36751250; PMCID: PMC9899104","journal-title":"Cureus"},{"issue":"12","key":"1930_CR21","doi-asserted-by":"publisher","first-page":"e0243045","DOI":"10.1371\/journal.pone.0243045","volume":"15","author":"Z Szak\u00e1cs","year":"2020","unstructured":"Szak\u00e1cs Z, Hegyi PJ, Farkas N, Hegyi P, Balask\u00f3 M, Er\u0151s A, Szuj\u00f3 S, Pammer J, Mosd\u00f3si B, Simon M, Nagy A, F\u00fcr G, Hussain A (2020) Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a systematic review. PLoS ONE 15(12):e0243045. https:\/\/doi.org\/10.1371\/journal.pone.0243045. PMID: 33270732; PMCID: PMC7714354","journal-title":"PLoS ONE"},{"key":"1930_CR22","doi-asserted-by":"crossref","unstructured":"Nesr G, Claudiani S, Milojkovic D, Innes A, Fernando F, Caballes I, Mungozi P, Szydlo R, Lovato S, Jayasena C, Apperley J Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia. Leuk Lymphoma. 2024 Apr 23:1\u20136. doi: 10.1080\/10428194.2024.2343758. Epub ahead of print. PMID: 38652865","DOI":"10.1080\/10428194.2024.2343758"},{"issue":"4","key":"1930_CR23","doi-asserted-by":"publisher","first-page":"e0152872","DOI":"10.1371\/journal.pone.0152872","volume":"11","author":"V Bernard","year":"2016","unstructured":"Bernard V, Bouilly J, Kramer P, Carre N, Schlumberger M, Visser JA et al (2016) The tyrosine kinase inhibitor Sunitinib affects Ovulation but not ovarian Reserve in mouse: a preclinical study. PLoS ONE 11(4):e0152872","journal-title":"PLoS ONE"},{"issue":"12","key":"1930_CR24","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G (2012) Off-target effects of BCR- ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 53(12):2351\u20132361","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1930_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2007.09.017","volume":"108","author":"S Chu","year":"2008","unstructured":"Chu S, Alexiadis M, Fuller PJ (2008) Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol 108(1):182\u2013190","journal-title":"Gynecol Oncol"},{"issue":"10","key":"1930_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMc0707841","volume":"358","author":"C Christopoulos","year":"2008","unstructured":"Christopoulos C, Dimakopoulou V, Rotas E (2008) Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 358(10):1079\u20131080","journal-title":"N Engl J Med"},{"key":"1930_CR27","doi-asserted-by":"crossref","unstructured":"Zamah AM, Mauro MJ, Druker BJ, Oktay K, Egorin MJ, Cedars MI et al (2011) Will Imatinib Compromise Reproductive Capacity? Oncologist 16(10):1422\u20131427","DOI":"10.1634\/theoncologist.2011-0137"},{"issue":"10","key":"1930_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nm.2033","volume":"15","author":"S Gonfloni","year":"2009","unstructured":"Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C et al (2009) Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15(10):1179\u20131185","journal-title":"Nat Med"},{"issue":"8","key":"1930_CR29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2889","volume":"18","author":"JB Kerr","year":"2012","unstructured":"Kerr JB, Hutt KJ, Cook M, Speed TP, Strasser A, Findlay JK et al (2012) Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med 18(8):1170\u20131172 author reply 2\u20134","journal-title":"Nat Med"},{"key":"1930_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/cdd.2013.31","volume":"20","author":"SY Kim","year":"2013","unstructured":"Kim SY, Cordeiro M, Serna V, Ebbert K, Butler LM, Sinha S et al (2013) Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network. Cell Death Differ 20:987\u2013997","journal-title":"Cell Death Differ"},{"issue":"3","key":"1930_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.leukres.2011.09.025","volume":"36","author":"B Schultheis","year":"2012","unstructured":"Schultheis B, Nijmeijer BA, Yin H, Gosden RG, Melo JV (2012) Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 36(3):271\u2013274","journal-title":"Leuk Res"},{"issue":"7","key":"1930_CR32","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1371\/journal.pone.0070117","volume":"8","author":"S Morgan","year":"2013","unstructured":"Morgan S, Lopes F, Gourley C, Anderson RA, Spears N (2013) Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS ONE 8(7):e70117","journal-title":"PLoS ONE"},{"key":"1930_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01846-3","author":"T Satija","year":"2024","unstructured":"Satija T, Suri V, Arora A et al (2024) Effect of Imatinib Mesylate on the ovarian reserves of female patients with chronic myeloid leukaemia. Indian J Hematol Blood Transfus. https:\/\/doi.org\/10.1007\/s12288-024-01846-3","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"12","key":"1930_CR34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF (2015) The impact of dasatinib on pregnancy outcomes. Am J Hematol 90(12):1111\u20131115. https:\/\/doi.org\/10.1002\/ajh.24186. Epub 2015 Oct 12. PMID: 26348106; PMCID: PMC5115878","journal-title":"Am J Hematol"},{"issue":"2","key":"1930_CR35","doi-asserted-by":"publisher","first-page":"IJH26","DOI":"10.2217\/ijh-2020-0004","volume":"9","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Br\u00fcmmendorf TH (2020) Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol 9(2):IJH26. https:\/\/doi.org\/10.2217\/ijh-2020-0004. PMID: 33005329; PMCID: PMC7510513","journal-title":"Int J Hematol Oncol"},{"issue":"4","key":"1930_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2023.11.011","volume":"24","author":"E Abruzzese","year":"2024","unstructured":"Abruzzese E, Trawinska MM, De Fabritiis P, Bernardi S (2024) SOHO State of the art updates and next questions: chronic myeloid leukemia and pregnancy: per Aspera Ad Astra. Clin Lymphoma Myeloma Leuk 24(4):214\u2013223 Epub 2023 Dec 12. PMID: 38151389","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1930_CR37","doi-asserted-by":"crossref","unstructured":"Glick I, Kadish E, Rottenstreich M (2021) Management of Pregnancy in Women of Advanced Maternal Age: Improving Outcomes for Mother and Baby. Int J Womens Health.;13:751\u2013759. doi: 10.2147\/IJWH.S283216. Erratum in: Int J Womens Health. 2023;15:1621\u20131622. doi: 10.2147\/IJWH.S445754. PMID: 34408501; PMCID: PMC8364335","DOI":"10.2147\/IJWH.S283216"},{"issue":"5","key":"1930_CR38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5. Epub 2016 Feb 3. PMID: 26837842; PMCID: PMC4858585","journal-title":"Leukemia"},{"issue":"20","key":"1930_CR39","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-Year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333\u20132340 Epub 2016 May 23. PMID: 27217448; PMCID: PMC5118045","journal-title":"J Clin Oncol"},{"issue":"4","key":"1930_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41375-024-02183-0","volume":"38","author":"E Chelysheva","year":"2024","unstructured":"Chelysheva E, Apperley J, Turkina A, Yassin MA, Rea D, Nicolini FE, Barraco D, Kazakbaeva K, Saliev S, Abulafia AS, Al-Kindi S, Byrne J, Robertson HF, Cerrano M, Shmakov R, Polushkina E, de Fabritiis P, Trawinska MM, Abruzzese E (2024) Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry. Leukemia 38(4):788\u2013795. https:\/\/doi.org\/10.1038\/s41375-024-02183-0. Epub 2024 Feb 23. PMID: 38388649","journal-title":"Leukemia"},{"issue":"11","key":"1930_CR41","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1634\/theoncologist.2019-0109","volume":"24","author":"X Dou","year":"2019","unstructured":"Dou X, Qin Y, Huang X, Jiang Q (2019) Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Oncologist 24(11):e1141\u2013e1147. https:\/\/doi.org\/10.1634\/theoncologist.2019-0109. Epub 2019 Jun 11. PMID: 31186377; PMCID: PMC6853119","journal-title":"Oncologist"},{"issue":"8","key":"1930_CR42","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00277-023-05280-9","volume":"102","author":"RC Malik","year":"2023","unstructured":"Malik RC, Sahoo PS, Sharawat RK, Singh S, Garg M, Bhatia V, Kantak K, Kumar A, Kumar S (2023) Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution. Ann Hematol 102(8):2087\u20132096. https:\/\/doi.org\/10.1007\/s00277-023-05280-9. Epub 2023 Jun 15. PMID: 37322094","journal-title":"Ann Hematol"},{"key":"1930_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01743-9","author":"U Bhattacharjee","year":"2024","unstructured":"Bhattacharjee U, Singh C, Jandial A et al (2024) Maternal and foetal outcomes of newly diagnosed chronic myeloid leukemia during pregnancy and its long-term impact. Indian J Hematol Blood Transfus 40(4);687\u2013693. https:\/\/doi.org\/10.1007\/s12288-024-01743-9","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"1930_CR44","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1016\/j.leukres.2009.07.010","volume":"34","author":"O Salomon","year":"2010","unstructured":"Salomon O, Tohami T, Trakhtenbrot L, Meirov R, Kneller A, Berkowitz M, Nagler A, Sivan E, Goldman JM, Rechavi G, Amariglio N (2010) BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnant. Leuk Res 34(2):e78\u201381 Epub 2009 Jul 28. PMID: 19640586","journal-title":"Leuk Res"},{"issue":"4","key":"1930_CR45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/10428194.2020.1849672","volume":"62","author":"R Assi","year":"2021","unstructured":"Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE (2021) Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience. Leuk Lymphoma 62(4):909\u2013917 Epub 2020 Dec 7. PMID: 33283580","journal-title":"Leuk Lymphoma"},{"key":"1930_CR46","doi-asserted-by":"publisher","first-page":"702929","DOI":"10.3389\/frph.2021.702929","volume":"3","author":"M Zhang","year":"2021","unstructured":"Zhang M, Fu S, Ren D, Wu Y, Yao N, Ni T et al (2021) Maternal and fetal outcomes after Interferon exposure during pregnancy: a systematic review with Meta-analysis. Front Reprod Health 3:702929. https:\/\/doi.org\/10.3389\/frph.2021.702929","journal-title":"Front Reprod Health"},{"key":"1930_CR47","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission Recommendations for the Use of Antiretroviral Drugs During Pregnancy an Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal. Accessed (09\/10\/2024)"},{"key":"1930_CR48","doi-asserted-by":"publisher","unstructured":"Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ, Knight K, Mahdi AJ, Parker J, Virchis A, Apperley JF (2024) Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy. Br J Haematol. May 2. https:\/\/doi.org\/10.1111\/bjh.19491. Epub ahead of print. PMID: 38698705","DOI":"10.1111\/bjh.19491"},{"issue":"6","key":"1930_CR49","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","volume":"116","author":"A Kuwabara","year":"2010","unstructured":"Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D (2010) Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014\u20131016. https:\/\/doi.org\/10.1182\/blood-2010-04-280206. PMID: 20705771; PMCID: PMC2924222","journal-title":"Blood"},{"issue":"1","key":"1930_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12288-015-0519-0","volume":"32","author":"M Rohilla","year":"2016","unstructured":"Rohilla M, Rai R, Yanamandra U, Chaudhary N, Malhotra P, Varma N, Jain V, Prasad GR, Kalra J, Varma SC (2016) Obstetric complications and management in chronic myeloid leukemia. Indian J Hematol Blood Transfus 32(1):62\u201366. https:\/\/doi.org\/10.1007\/s12288-015-0519-0. Epub 2015 Feb 26. PMID: 26855508; PMCID: PMC4733674","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"1930_CR51","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1002\/ajh.26424","volume":"97","author":"FM Santos","year":"2022","unstructured":"Santos FM, Ghelfond G, Seguro FS, Abdo ANR, Dalessandro T, Maciel FVR, Bassolli L, Rocha V, Bendit I (2022) Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia. Am J Hematol 97(2):E72\u2013E74. https:\/\/doi.org\/10.1002\/ajh.26424. Epub 2021 Nov 30. PMID: 34822180","journal-title":"Am J Hematol"},{"issue":"3","key":"1930_CR52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/1078155220948942","volume":"27","author":"R Terao","year":"2021","unstructured":"Terao R, Nii M, Asai H, Nohara F, Okamoto T, Nagaya K, Azuma H (2021) Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy. J Oncol Pharm Pract 27(3):756\u2013760 Epub 2020 Aug 12. PMID: 32787559","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1930_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-019-01074-0","volume":"35","author":"U Yanamandra","year":"2019","unstructured":"Yanamandra U, Malhotra P (2019) CML in India: are we there yet? Indian J Hematol Blood Transfus 35(1):1\u20132. https:\/\/doi.org\/10.1007\/s12288-019-01074-0. Epub 2019 Jan 17. PMID: 30828139; PMCID: PMC6369077","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01930-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01930-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01930-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:31:13Z","timestamp":1738686673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01930-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01930-8","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review article and does not require clearance from ethics committee. It is not under consideration for publication elsewhere and that, if accepted, it will not be published elsewhere in the same form, in English or any other language, including electronically. All authors have approved of the final article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}